Page URL:

DNA test for prostate cancer relapse shows promise

15 May 2012
Appeared in BioNews 656

A blood test for men with prostate cancer could indicate whether their cancer is likely to recur after treatment, and if so, how aggressively, say researchers from the University of Pittsburg School of Medicine, USA.

A study to investigate whether prostate cancer relapse can be predicted by looking at genetic abnormities using tissue samples from tumours as well as from neighbouring tissues and blood samples had promising results. It could mean that less invasive tests could be used after a patient's initial treatment to see if further treatment is needed. Patients could be spared further aggressive treatments if their cancer is found to be slow-growing and therefore unlikely to cause death.

Dr Jianhua Luo and his colleagues analysed the genomes of 104 prostate tumour samples, 85 blood samples and 49 samples of benign prostate tissue adjacent to tumours to identify copy number variations (CNVs). A CNV represents an abnormal number of copies of one or more sections of DNA. Samples from all three tissue/blood groups showed CNVs, some with similar deletion and amplification patterns. Using this data, the researchers were able to build a prediction model to identify patients at risk of relapse.

The researchers found that CNVs from prostate tumour tissue could predict the chance of relapse with significant accuracy, at 73 percent. Similarly, CNVs from these tissues could predict cancer aggression with 75 percent accuracy - although as the study was conducted in patients who had already undergone the removal of all or part of the prostate, the test did not identify benign tumours from aggressive ones before treatment.

Blood samples also had high predictive accuracy - at 81 percent for relapse and 69 percent for aggression; as did neighbouring benign prostate tissue samples - at 67 percent for relapse and 77 percent for aggression.

'For a patient already having a radical prostatectomy, CNV analysis on the tumour or blood sample may help to decide whether additional treatment is warranted to prevent relapse. Despite some limitations, including the need for high quality genome DNA, CNV analysis on the genome of blood, normal prostate, or tumour tissues holds promise to become a more efficient and accurate way to predict the behaviour of prostate cancer', said Dr Luo.

Reporting on the study, the Daily Mail said a blood test is likely to be several years away. The results of the study will need to be validated with further research and an inexpensive blood test developed before such a test could reach the market.

Blood test clue to prostate cancer
Press Association |  7 May 2012
Blood test for missing or damaged DNA could provide hint of a prostate cancer relapse
Daily Mail |  7 May 2012
DNA test for prostate cancer relapse
NHS Choices: Behind the Headline |  8 May 2012
Genome Abnormalities Precede Prostate Cancer and Predict Clinical Relapse
The American Journal of Pathology |  6 May 2012
Genome Variation in Prostate Tumors and Blood Samples Could Help Predict Disease Progression, Says Pitt Team
Health Canal (press release) |  8 May 2012
15 July 2013 - by Julianna Photopoulos 
Scientists have developed a 'barcode' blood test that reads genetic changes to pick out the most aggressive prostate cancers...
28 May 2013 - by James Brooks 
A British man has had his prostate removed after testing positive for a mutation in the BRCA2 gene known to greatly increase the risk of cancer. The operation is thought to be the first prostatectomy performed due to an assessment of genetic risk...
13 May 2013 - by Daryl Ramai 
A genetic test released in the USA claims to be able to score the aggressiveness of prostate cancer before medical intervention, helping men with the condition decide if and when to start receiving treatment....
18 March 2013 - by Dr Nicola Davis 
A blood test is being developed that could help doctors monitor how breast cancer tumours respond to therapy...
8 May 2012 - by Dr Kimberley Bryon-Dodd 
A link between modifications to a white blood cell gene and an increased risk of breast cancer could be the basis for a simple blood test to identify women most at risk of developing the disease...
27 February 2012 - by Ayesha Jadoon 
A handheld device for sequencing DNA on the move has been unveiled by UK company Oxford Nanopore. The single-use MinION tool resembles a USB drive in size and shape, and the company hopes it will be put into routine use by clinicians and researchers alike...
22 August 2011 - by Sarah Pritchard 
US researchers have made a discovery that might help doctors distinguish between benign and more aggressive forms of prostate cancer. The team reports that a difference in the genetic make-up of prostate tumours could indicate which are likely to metastasize and spread through the body, and which will be slow-growing and non-fatal...
16 May 2011 - by Dr Kimberley Bryon-Dodd 
Screening for breast and prostate cancer based on genetic risk factors as well as age could reduce the number of people screened without a significant reduction in the number of cancers detected, a new study suggests....
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.